PriceTargets.com logo

Pliant Therapeutics - PLRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.50
  • Forecasted Upside: 206.59%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$13.21 As of 12/20/2024 06:16 PM ET
▼ -0.09 (-0.68%)

This chart shows the closing price for PLRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pliant Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLRX

Analyst Price Target is $40.50
▲ +206.59% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Pliant Therapeutics in the last 3 months. The average price target is $40.50, with a high forecast of $45.00 and a low forecast of $33.00. The average price target represents a 206.59% upside from the last price of $13.21.

This chart shows the closing price for PLRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Pliant Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
9/9/2024Leerink PartnrsUpgradeStrong-Buy
9/9/2024Leerink PartnersInitiated CoverageOutperform$46.00 ➝ $33.00
8/12/2024HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $38.00
8/8/2024Cantor FitzgeraldReiterated RatingOverweight
8/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
8/8/2024OppenheimerLower TargetOutperform ➝ Outperform$48.00 ➝ $45.00
7/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
7/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
6/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
5/7/2024CitigroupLower TargetBuy ➝ Buy$45.00 ➝ $44.00
5/7/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$54.00 ➝ $45.00
5/7/2024OppenheimerBoost TargetOutperform ➝ Outperform$47.00 ➝ $48.00
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00
4/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00
3/5/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$50.00 ➝ $54.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00
2/28/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$53.00 ➝ $50.00
2/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$38.00
2/5/2024Needham & Company LLCLower TargetBuy ➝ Buy$45.00 ➝ $38.00
2/5/2024HC WainwrightLower TargetBuy ➝ Buy$52.00 ➝ $48.00
12/8/2023Wells Fargo & CompanyInitiated CoverageOverweight$41.00
11/10/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$54.00 ➝ $53.00
10/16/2023Leerink PartnrsReiterated RatingOutperform
10/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
9/27/2023HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $52.00
9/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
8/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$63.00
8/10/2023OppenheimerBoost TargetOutperform ➝ Outperform$51.00 ➝ $52.00
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$47.00 ➝ $48.00
8/10/2023Royal Bank of CanadaLower Target$57.00 ➝ $54.00
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/8/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$57.00
5/18/2023Canaccord Genuity GroupInitiated CoverageBuy$48.00
5/15/2023Cantor FitzgeraldReiterated RatingOverweight
5/10/2023HC WainwrightLower Target$55.00 ➝ $50.00
5/10/2023OppenheimerBoost Target$44.00 ➝ $51.00
5/1/2023Cantor FitzgeraldBoost Target$52.00 ➝ $63.00
5/1/2023HC WainwrightBoost Target$54.00 ➝ $55.00
4/20/2023Needham & Company LLCReiterated RatingBuy$45.00
4/12/2023Robert W. BairdInitiated CoverageOutperform$44.00
3/28/2023HC WainwrightReiterated RatingBuy$54.00
3/20/2023HC WainwrightBoost Target$53.00 ➝ $54.00
3/13/2023CitigroupLower TargetBuy$55.00 ➝ $50.00
3/10/2023Needham & Company LLCReiterated RatingBuy$45.00
3/10/2023JPMorgan Chase & Co.Lower TargetOverweight$51.00 ➝ $47.00
3/10/2023OppenheimerBoost TargetOutperform$43.00 ➝ $44.00
3/10/2023Royal Bank of CanadaLower TargetOutperform$60.00 ➝ $58.00
1/24/2023Leerink PartnersBoost TargetOutperform$33.00 ➝ $45.00
1/24/2023CitigroupBoost TargetBuy$36.00 ➝ $55.00
1/23/2023Needham & Company LLCBoost TargetBuy$40.00 ➝ $45.00
1/23/2023JPMorgan Chase & Co.Boost Target$42.00 ➝ $51.00
1/23/2023Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $52.00
12/13/2022Stifel NicolausInitiated CoverageBuy$33.00
12/7/2022JPMorgan Chase & Co.Initiated CoverageOverweight$42.00
11/9/2022Royal Bank of CanadaLower TargetOutperform$52.00 ➝ $50.00
9/1/2022CitigroupInitiated CoverageBuy$36.00
8/9/2022HC WainwrightBoost TargetBuy$45.00 ➝ $53.00
7/20/2022Leerink PartnersInitiated CoverageOutperform$33.00
7/11/2022Piper SandlerBoost Target$27.00 ➝ $40.00
7/11/2022Cantor FitzgeraldBoost Target$28.00 ➝ $36.00
7/11/2022Royal Bank of CanadaBoost Target$35.00 ➝ $54.00
5/25/2022Cantor FitzgeraldInitiated CoverageOverweight$28.00
5/17/2022Piper SandlerLower TargetOverweight$63.00 ➝ $27.00
5/10/2022Needham & Company LLCReiterated RatingBuy$40.00
12/9/2021OppenheimerInitiated CoverageOutperform$40.00
11/23/2021Royal Bank of CanadaInitiated CoverageOutperform$38.00
11/3/2021HC WainwrightInitiated CoverageBuy$45.00
8/10/2021Needham & Company LLCInitiated CoverageBuy$40.00
4/22/2021Piper SandlerBoost TargetOverweight$50.00 ➝ $63.00
4/20/2021BTIG ResearchInitiated CoverageBuy$51.00
4/5/2021CitigroupInitiated CoverageBuy
8/12/2020Needham & Company LLCReiterated RatingBuy$40.00
6/29/2020CowenInitiated CoverageOutperform
6/29/2020Needham & Company LLCInitiated CoverageBuy$40.00
6/29/2020CitigroupInitiated CoverageBuy$40.00
6/29/2020Piper SandlerInitiated CoverageOverweight$50.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Pliant Therapeutics logo
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $13.21
Low: $13.07
High: $13.85

50 Day Range

MA: $14.08
Low: $12.32
High: $15.70

52 Week Range

Now: $13.21
Low: $10.22
High: $19.62

Volume

1,874,293 shs

Average Volume

469,309 shs

Market Capitalization

$803.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Pliant Therapeutics?

The following sell-side analysts have issued research reports on Pliant Therapeutics in the last year: Cantor Fitzgerald, Citigroup Inc., HC Wainwright, Leerink Partners, Leerink Partnrs, Needham & Company LLC, Oppenheimer Holdings Inc., and Royal Bank of Canada.
View the latest analyst ratings for PLRX.

What is the current price target for Pliant Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Pliant Therapeutics in the last year. Their average twelve-month price target is $40.50, suggesting a possible upside of 206.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting PLRX will reach $45.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $33.00 for Pliant Therapeutics in the next year.
View the latest price targets for PLRX.

What is the current consensus analyst rating for Pliant Therapeutics?

Pliant Therapeutics currently has 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLRX will outperform the market and that investors should add to their positions of Pliant Therapeutics.
View the latest ratings for PLRX.

What other companies compete with Pliant Therapeutics?

Other companies that are similar to Pliant Therapeutics include Edgewise Therapeutics, Janux Therapeutics, Xenon Pharmaceuticals, Merus and ACADIA Pharmaceuticals. Learn More about companies similar to Pliant Therapeutics.

How do I contact Pliant Therapeutics' investor relations team?

Pliant Therapeutics' physical mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-481-6770 and its investor relations email address is [email protected]. The official website for Pliant Therapeutics is pliantrx.com. Learn More about contacing Pliant Therapeutics investor relations.